Floatz logo

18 assets in Small Cell Carcinoma

Therapeutic assets addressing Small Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Nogitecan
Small Cell Carcinoma
National Cancer Institute (NCI)P2BB (67)
Etoposide
Small Cell Carcinoma
SystImmune Inc.P3BB (66)
Lurbinectedin
Small Cell Carcinoma
SystImmune Inc.P3BB (66)
Pembrolizumab
Small Cell Carcinoma
Thomas Jefferson UniversityP2BB (65)
Berzosertib
Small Cell Carcinoma
National Cancer Institute (NCI)P2BB (64)
Carboplatin
Small Cell Carcinoma
SystImmune Inc.P3BB (64)
Atezolizumab
Small Cell Carcinoma
SystImmune Inc.P3B (60)
Bl-M14D1
Small Cell Carcinoma
SystImmune Inc.P3B (60)
Abiraterone
Small Cell Carcinoma
MacroGenicsP2CCC (53)
Apalutamide
Small Cell Carcinoma
Rahul AggarwalP2CCC (53)
Cetrelimab
Small Cell Carcinoma
Rahul AggarwalP2CCC (53)
Durvalumab
Small Cell Carcinoma
Gruppo Oncologico Italiano di Ricerca ClinicaP2CCC (53)
Enzalutamide
Small Cell Carcinoma
MacroGenicsP2CCC (53)
1-(4,4-BIS(P-FLUOROPHENYL)BUTYL)-4-(4-CHLORO-.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-M-TOLYL)-4-PIPERIDINOL
Small Cell Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyP1/2CC (47)
Tarlatamab
Small Cell Carcinoma
National Cancer Institute (NCI)P1/2CC (47)
Definity
Small Cell Carcinoma
Thomas Jefferson UniversityP1CC (43)
Vobramitamab Duocarmazine
Small Cell Carcinoma
MacroGenicsP2C (36)
exs74539
Small Cell Carcinoma
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.P1NR ()